
CMRI is delighted by the NSW Government’s announcement about the establishment of Australia’s first commercial-scale viral vector manufacturing facility in the Westmead Health and Innovation District.
The ability to manufacture high-quality (clinical grade) viral vectors in Australia is critically important for our gene therapy programs. It will accelerate the delivery of, and access to, life-saving new gene therapies developed in the CMRI labs led by Professor Ian Alexander, Associate Professor Leszek Lisowski, Dr Anai Gonzalez-Cordero and Professor Robyn Jamieson, with our partner organisation, SCHN, to Australian patients, and transform the lives of many Australian families.